Sclerosis News and Research

RSS

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Women who are pregnant or using synthetic progesterone birth control injections have a conspicuous vulnerability to certain infections including malaria, Listeria, HIV, and herpes simplex virus.

2 Mar 2013

DDR may help decrease cognitive and physical effects of multiple sclerosis

Studies have shown that the popular video game, Dance Dance Revolution (DDR), which requires players to coordinate their movements to the beat of music, may help improve balance and mobility in certain patient populations.

28 Feb 2013

ECGs show structural difference in brain connections among children with autism

A look at how the brain processes information finds a distinct pattern in children with autism spectrum disorders. Using EEGs to track the brain's electrical cross-talk, researchers from Boston Children's Hospital have found a structural difference in brain connections. Compared with neurotypical children, those with autism have multiple redundant connections between neighboring brain areas at the expense of long-distance links.

27 Feb 2013

New journal aims to address fatigue in medical illnesses and specific environmental conditions

With peer-reviewed articles on fatigue having increased 90% over the past decade - and nearly 1,000 papers on the topic published in 2011 alone - the time is right for Routledge's new journal, Fatigue: Biomedicine, Health & Behavior.

27 Feb 2013

Natalizumab may be second-line option for pediatric MS patients

Natalizumab may be an effective and well tolerated second-line treatment for pediatric patients with highly active relapsing-remitting multiple sclerosis, say researchers.

26 Feb 2013

Cleveland Clinic receives $1.97M NIMH grant for innovative autism research

The National Institute of Mental Health (NIMH) has awarded $1.97 million for innovative autism research to Bruce Trapp, Ph.D., Chairman of Neurosciences at Cleveland Clinic's Lerner Research Institute.

26 Feb 2013

Imatinib can relieve and slow down progression of multiple sclerosis

A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE.

21 Feb 2013

NINDS to award TSRI scientist with $3.5M Jacob K. Javits Neuroscience Investigator Award

Ron Davis, PhD, chair of the Neuroscience Department on the Florida campus of The Scripps Research Institute, has been selected to receive a prestigious $3.5 million Jacob K. Javits Neuroscience Investigator Award for his work on the complex biology of memory formation and the disorders that disrupt it.

21 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Study may help design better DAA drug cocktails to treat HCV

Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs.

20 Feb 2013

FDA committee recommends approval of Guerbet’s Dotarem NDA for adults and children

Guerbet, the contrast agent specialist for medical imaging, today announced that the Medical Imaging Drugs Advisory Committee to US Food and Drug Administration (FDA) has voted unanimously by votes of 17 to 0 to recommend that FDA approve the New Drug Application (NDA) for Dotarem (gadoterate meglumine) for adults, and for pediatric use for children two years of age and older.

15 Feb 2013

Study demonstrates how CN2097 works to restore neural functions impaired by Angelman syndrome

In a new study in mice, a scientific collaboration centered at Brown University lays out in unprecedented detail a neurological signaling breakdown in Angelman syndrome, a disorder that affects thousands of children each year, characterized by developmental delay, seizures, and other problems.

14 Feb 2013

New medication could help patients with renal tumours triggered by tuberous sclerosis

In collaboration with the Berlin TSC Centre, Charité - Universitätsmedizin Berlin has developed a new therapy for patients suffering from renal tumours associated with the rare genetic disease tuberous sclerosis (TSC).

13 Feb 2013

Study finds abnormal production of C9RANT in patients with ALS, frontotemporal dementia

Researchers at Mayo Clinic have discovered an abnormal protein that accumulates in the brains of many patients affected with two common neurodegenerative disorders — amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, and frontotemporal dementia.

13 Feb 2013

Scientists identify enigmatic aggregates linked to neurodegenerative diseases

The proteins that have now been identified shouldn't actually exist. Nevertheless, they build the core of cellular aggregates whose identity has been enigmatic until now. These aggregates are typically associated with hereditary neurodegenerative diseases including variants of frontotemporal dementia (FTD), also known as frontotemporal lobar degeneration (FTLD), and amyotrophic lateral sclerosis (ALS). They are likely to be damaging and might be a target for therapy.

11 Feb 2013

Scientists discover natural trigger that enables stem cell development

A natural trigger that enables stem cells to become any cell-type in the body has been discovered by scientists.

10 Feb 2013

Infusions of regulatory T cells turn off autoimmune attack on joints

Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model. They say it holds promise for improved treatment of arthritis and other autoimmune disorders in people.

10 Feb 2013

Harvard's Wyss Institute completes first clinical study of new rapid neuroassessment device

Doctors routinely track their patients' hand-eye coordination to monitor any neuromuscular deficits, particularly as patients age or when they are injured -- but the tests they have been using to track this kind of information may be subjective and qualitative.

10 Feb 2013

Reprogrammed human skin cells highly effective in treating myelin disorders

A study out today in the journal Cell Stem Cell shows that human brain cells created by reprogramming skin cells are highly effective in treating myelin disorders, a family of diseases that includes multiple sclerosis and rare childhood disorders called pediatric leukodystrophies.

10 Feb 2013

Occupational exposure to magnetic fields may moderately increase risk of Alzheimer's, ALS

Occupational exposure to magnetic fields (MF) may be associated with "moderately increased risk" of certain neurodegenerative diseases—including Alzheimer's and amyotrophic lateral sclerosis, reports the February Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

7 Feb 2013

Sclerosis News and Research

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

DDR may help decrease cognitive and physical effects of multiple sclerosis

ECGs show structural difference in brain connections among children with autism

New journal aims to address fatigue in medical illnesses and specific environmental conditions

Natalizumab may be second-line option for pediatric MS patients

Cleveland Clinic receives $1.97M NIMH grant for innovative autism research

Imatinib can relieve and slow down progression of multiple sclerosis

NINDS to award TSRI scientist with $3.5M Jacob K. Javits Neuroscience Investigator Award

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Study may help design better DAA drug cocktails to treat HCV

FDA committee recommends approval of Guerbet’s Dotarem NDA for adults and children

Study demonstrates how CN2097 works to restore neural functions impaired by Angelman syndrome

New medication could help patients with renal tumours triggered by tuberous sclerosis

Study finds abnormal production of C9RANT in patients with ALS, frontotemporal dementia

Scientists identify enigmatic aggregates linked to neurodegenerative diseases

Scientists discover natural trigger that enables stem cell development

Infusions of regulatory T cells turn off autoimmune attack on joints

Harvard's Wyss Institute completes first clinical study of new rapid neuroassessment device

Reprogrammed human skin cells highly effective in treating myelin disorders

Occupational exposure to magnetic fields may moderately increase risk of Alzheimer's, ALS

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News